12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Solorel macimorelin regulatory update

Aeterna Zentaris said FDA did not grant Fast Track designation for AEZS-130 to diagnose adult growth hormone deficiency. Aeterna declined to disclose details. The company said...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >